Navigation Links
Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
Date:7/25/2011

MISSISSAUGA, Ontario, July 25, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that its wholly owned subsidiary, Valeant Canada Limited, has received notice that the New Drug Submission for Sublinox has been approved from the Canadian regulatory authority Health Canada.  Sublinox (zolpidem tartrate) is indicated for the short-term treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.  The product will be commercialized by the joint venture between Meda AB and Valeant Canada Limited (Meda Valeant Pharma Canada Inc.).

"We are excited to receive approval for our second product to come out of our joint venture with Meda," said J. Michael Pearson, chairman and chief executive officer.  "With this approval, we currently anticipate launching this product in the fourth quarter, just one of several pending product launches that our Canadian operations plan on initiating before the end of the year."

Information about Sublinox

Sublinox is a sublingual orally dissolving tablet of zolpidem tartrate and will be the first commercially available zolpidem tartrate formulation in Canada.  Sublinox has been clinically demonstrated to initiate a statistically significant latency to persistent sleep (LPS), Sleep onset latency (SOL), and Latency to stage 1 sleep (ST1L) in comparison to oral zolpidem tartrate.  Analysis of sleep continuity endpoints, total sleep time (TST) and wake after sleep onset (WASO) showed no major treatment differences in comparison to oral zolpidem tartrate tablets.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Caution Regarding Forward-Looking Information

To the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

These forward-looking statements relate to, among other things, the expected launch time of Sublinox, the impact of Sublinox on our product portfolio in Canada, our ability to leverage our capabilities with new products, and the growth opportunities of Valeant Canada.  Forward-looking statements can generally be identified by the use of words such as "believe", "anticipate", "expect", "estimate", "intend", "continue", "plan", "project", "will", "may", "should", "could", "would", "target", "potential" and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission and the Canadian Securities Administrators.  

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 Exactus ... company providing high-quality specialty pharmacy care for those ... today it has achieved full Specialty Pharmacy Accreditation ... organization dedicated to promoting health care quality through ... --> The URAC accreditation process ...
(Date:2/11/2016)... , Feb. 11, 2016 Scientists from ... method that opens the door to genetic analysis ... have been impossible to isolate with 100 percent ... specific tumor types in various stages of development, ... of these cells that are clinically relevant, and ...
(Date:2/11/2016)... , Feb. 11, 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... will be made at the 38th annual John ... Care Symposium, which is being held February 14-18, 2016 ... covers the latest advancements in wound healing, burn care, ... Burn Association, Australian-New Zealand Burns Association, Academy of Physicians ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... with their ongoing community involvement program, introduces a new charity campaign to raise ... donations are now being accepted at https://donate.rmhc.org/ . , Ronald McDonald House ...
(Date:2/11/2016)... ... 2016 , ... Be Well Medical Group (Be Well) is pleased ... at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is ... the convenience of their homes, offices or at the practices’ local office. It is ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling ... in health and wellness best practices in the past couple of decades, and ... is American Heart Month, which acts as an exceptional opportunity to revise food ...
(Date:2/10/2016)... ... February 10, 2016 , ... President ... Medicare Advantage organizations to deliver medical services via telehealth, estimated to generate more ... advocating for such language for many years. Although there is more to ...
(Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and delivered ... order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige Delivery ... only 15 miles away from Flint. , “We have deep roots in the local ...
Breaking Medicine News(10 mins):